TAIPEI and SAN DIEGO, Dec. 1, 2022 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases , announced that their first in class new drug Pidnarulex (CX-5461) , has been successfully selected to the anticancer pipeline of NIH-sponsored NExT Program (NCI Experimental Therapeutics Program), which will foster the exploration of its therapeutic potential in unmet medical needs and advancement to market. .
TAIPEI and SAN DIEGO, Jan. 25, 2022 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced today that the US Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for Pidnarulex, a first-in-class G-quadruplex stabilizer, for the treatment of patients with breast and ovarian cancers BRCA1/2, PALB2, or other HRD mutations.
Senhwa Biosciences, Inc., a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced that first patient has been successfully dosed, in a phase 1b clinical study of Pidnarulex as a potential treatment for solid tumors with Homologous Recombination (HR) gene mutations, at the Princess Margaret Cancer Centre in Toronto, Canada.